Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants ...